Association of Quality of Life in Patients with advanced Non-small Cell Lung Cancer and Anti-cancer Treatment Modalities: A longitudinal Study

• Main Authors: Hao-Wei Chen, 陳浩維
• Other Authors: Wei-Chu Chie
• Format: Others
• Language: zh-TW
• Published: 2019
• Online Access: http://ndltd.ncl.edu.tw/handle/yy5v6f

碩士 === 國立臺灣大學 === 流行病學與預防醫學研究所 === 107 === Background In more recent years, lung cancer is the major cause of oncologic-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer (85%). Because of delayed diagnosis, most NSCLC patients are diagnosed at an advanced-stage and predominantly receive palliative treatment. Treatment includes chemotherapy, radiotherapy, targeted therapy and immunotherapy. In view of incurable nature of advanced NSCLC, the goals of therapy should not only focus on attempts at controlling the disease, but it should also be directed at optimizing the patient’s quality of life (QoL). In the light of these various therapeutic options, it is clear that old version questionnaire cannot cover many important QoL issues or potential side-effects, so the objective of research is to evaluate the QoL of advanced-stage NSCLC patients receiving palliative anti-cancer modalities by using the latest questionnaire. Method This research design was a longitudinal design and utilizing convenience sampling. The participants for this study were recruited from the patients with advanced NSCLC and receiving anti-cancer treatment at National Taiwan University Hospital. The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and EORTC QLQ-LC29 were used to investigate changes in QoL. The data was analyzed by SAS 9.4. The continuous data were analyzed by t-test and the categorical data were analyzed by Chi-squared test. ANCOVA and Multiple regression was applied to analytic statistics., P<0.05 was defined as statistically significant. Result One hundred and four participants were included in the study. The median age of the participants was 63.6 years, and 55.8% were male. Compared three therapy mean difference after 4 to 6 weeks anti-cancer treatment. For the Global health status using immunotherapy improvement of quality of life, and for the Symptoms scales using targeted therapy improvement of diarrhea, but worsening of nausea and vomiting were observed (P <0.05). Conclusion Longitudinal QoL assessments are important in advanced lung cancer patients because the data they provide could, for example, evaluate the benefit and risk on QoL under different anti-cancer modalities for doctor to do decision making. During the treatment period, not only is it necessary trying to improve the quality of life for the functional scales and symptomatic scales, but also should pay attention to the adverse effect of the target therapy on physical functioning.